OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Review of Clinical Pharmacology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence	139
Blinding and expectancy confounds in psychedelic randomized controlled trials	116
Contraception and reproductive planning during the COVID-19 pandemic	71
The use of isotretinoin for acne – an update on optimal dosing, surveillance, and adverse effects	58
Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion	49
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications	42
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments	40
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis	39
An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations	37
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause	33
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors	31
Molecular docking and dynamics study to explore phytochemical ligand molecules against the main protease of SARS-CoV-2 from extensive phytochemical datasets	31
Switching biologics in psoriasis - practical guidance and evidence to support	30
An update on the complex relationship between clozapine and pneumonia	30
Activation of Nrf2 signaling pathway by natural and synthetic chalcones: a therapeutic road map for oxidative stress	29
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome	28
Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review	27
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations	27
Prediction of vancomycin dose on high-dimensional data using machine learning techniques	26
Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib	26
The potential role of interventions impacting on gut-microbiota in epilepsy	25
Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis	25
Strategies for recombinant production of antimicrobial peptides with pharmacological potential	24
Prevention of colistin induced nephrotoxicity: a review of preclinical and clinical data	23
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria	23